Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Redhill BiopharmaSTU:2RH 18 EV-to-EBIT is -6.87 as of Aug. 05, 2026. GuruFocus rates STU:2RH with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 690 Drug Manufacturers companies, Redhill Biopharma ranks worse than 144927.39% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Redhill Biopharma's Enterprise Value for the quarter that ended in Dec. 2025 was €39.47 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Redhill Biopharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-6.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Redhill Biopharma EV-to-EBIT Related Terms
Redhill Biopharma EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Redhill Biopharma's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2RH vs CTTH, SBFM, AKAN: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Redhill Biopharma EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Redhill Biopharma's EV-to-EBIT falls into.
Redhill Biopharma's current Enterprise Value is €47.56 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Redhill Biopharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-6.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Redhill Biopharma (STU:2RH) has a EV-to-EBIT of -6.87 as of Aug. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Redhill Biopharma and its competitors. According to the industry distribution chart, Redhill Biopharma ranks #999999 out of 690 companies in the Drug Manufacturers industry.
Is Redhill Biopharma's EV-to-EBIT too high?
Redhill Biopharma's current EV-to-EBIT is -6.87. Based on the distribution chart, Redhill Biopharma ranks #999999 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Redhill Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Redhill Biopharma's EV-to-EBIT compare to CTTH and SBFM?
According to the Drug Manufacturers industry distribution chart, Redhill Biopharma ranks #999999 out of 690 companies for EV-to-EBIT. This places Redhill Biopharma in the lower half of its industry. The industry median EV-to-EBIT is 15.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.57, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Redhill Biopharma and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Redhill Biopharma's current EV-to-EBIT is -6.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redhill Biopharma stock overvalued right now?
Redhill Biopharma (STU:2RH) has a current EV-to-EBIT of -6.87. The current EV-to-EBIT is -6.87. Redhill Biopharma's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Redhill Biopharma (STU:2RH), the current EV-to-EBIT is -6.87 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
18GF Score
Get the complete analysis for STU:2RH
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2RH has been successfully added to your 
